Emtricitabine/tenofovir alafenamide in HIV infection: Added benefit not proven

(Institute for Quality and Efficiency in Health Care) Partly no data were available, partly the appropriate comparator therapy was not adhered to. The risk of nervous system disorders was increased for one patient group.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news